3SBio, Inc. (SSRX) - 500 Beiträge pro Seite
eröffnet am 28.02.07 16:31:07 von
neuester Beitrag 15.08.07 08:34:10 von
neuester Beitrag 15.08.07 08:34:10 von
Beiträge: 6
ID: 1.115.212
ID: 1.115.212
Aufrufe heute: 0
Gesamt: 1.566
Gesamt: 1.566
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 10:48 | 131 | |
| vor 1 Stunde | 123 | |
| vor 46 Minuten | 120 | |
| gestern 23:42 | 106 | |
| gestern 21:58 | 105 | |
| vor 1 Stunde | 103 | |
| gestern 23:31 | 102 | |
| gestern 21:20 | 102 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.773,00 | -0,65 | 228 | |||
| 2. | 2. | 157,68 | -2,35 | 114 | |||
| 3. | 5. | 3,6700 | +6,84 | 101 | |||
| 4. | 3. | 6,7350 | -3,88 | 80 | |||
| 5. | 4. | 2.390,36 | +0,39 | 79 | |||
| 6. | 6. | 6,4580 | -2,87 | 60 | |||
| 7. | 7. | 22,780 | -4,96 | 49 | |||
| 8. | 8. | 7,4600 | -1,58 | 47 |
Feedback
Profile:3SBio, Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in China. Its product candidates are designed to address large markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company?s flagship product, EPIAO is an injectable recombinant human erythropoietin that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. It also offers TPIAO, a recombinant human thrombopoietin indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of platelets. In addition, the company markets two protein-based therapeutics, Intefen, a recombinant interferon alpha-2a product indicated for the treatment of carcinoma of the lymphatic or hematopoietic system and viral infectious diseases; and Inleusin, a recombinant human IL-2 product indicated for the treatment of renal cell carcinoma, metastatic melanoma, thoratic fluid build-up caused by cancer, and tuberculosis. Further, the company?s product pipeline includes various protein-based therapeutics, including NuPIAO, a second-generation EPIAO product candidate; NuLeusin, a next-generation Inleusin product candidate; TPIAO for the treatment of ITP; a human papilloma virus vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. 3SBio markets its products through a network of distributors to healthcare providers, including hospitals, clinics, and dialysis centers. The company was founded in 1993 and is headquartered in Shenyang, China.
http://www.3sbio.com/
http://www.3sbio.com/
??keiner dabei? Kein interesse????
Biosimilars And China: A Natural Combination, But Will It Happen?
Thursday June 14, 6:35 pm ET
ChinaBio Today submits: Biosimilars are the closest thing that the biotech world has to generic drugs. However, because biotech drugs are grown in cultures, rather than constructed out of chemicals like traditional pharma drugs, it is impossible to have a generic version of a biotech drug that is an exact reproduction of the original. This makes biosimilars difficult.
But biotech drugs are the most expensive drugs in the world, which makes generic versions of these famous medications very attractive.
At the moment, this is a dilemma. We know it will be solved, someday. We just don’t know how.
Because Asian drug centers, especially China and India, are known as low-cost havens of drug development, they are natural locations for developing these biosimilar drugs. Indeed, 3SBio (NasdaqGM: SSRX - News), the Chinese drug company that recently listed on the Nasdaq exchange (see story), is in the business of producing a version of Amgen’s (NasdaqGS: AMGN - News) EPO for the domestic Chinese market.
Amgen never patented EPO in China – it probably figured “What’s the point?” since Chinese IP laws were so weak at the time. This left 3SBio free to go ahead and make its own version of the drug to a population that, while huge, did not have much free cash to spend on a fairly esoteric drug. After all, the point of EPO is to lessen the effects of anemia in patients undergoing chemotherapy and dialysis, but the drug did nothing to cure the underlying cancer or kidney failure.
The patent protection on EPO and other early biotech drugs is running out. In fact, the patent on another Amgen biotech drug, Enbrel, expires in 2009. If these drugs were conventional medications, like Lipitor from Pfizer (NYSE: PFE - News), financial analysts would be climbing over each other to produce charts showing the rate at which Amgen’s revenues would fall in the coming years. Amgen has its own set of problems with EPO -- a well-documented story -- but the company remains much better off with its current difficulties than it would be if it faced imminent generic competition.
The reason that Amgen is off the hook on the patent expiration issue is that the FDA does not know how to devise a fair set of standards for approving biosimilars. Actually making one is fairly simple, despite the mystery in which biotech companies wrap their creations. Biotech companies obviously have a huge amount of self-interest in these rules. They believe that a biosimilar drug should, for the safety of the public, undergo a set of trials just as rigorous as the original. After all, they argue, the biosimilar drug is not the same, it is only similar. Small differences can make a life-and-death alteration. Safety is the goal, and all that. In all of this high-minded talk, no mention is ever made of the tremendous sums of money involved.
Consumers, tired of paying the enormous cost of these biotech drugs, argue for something less rigorous. The FDA, not sure what to do, stalls for time. In fact, the FDA dithered for so long over the first application for a biosimilar, a U.S. court told them to get moving. That initial application was for a human growth factor drug, Omnitrope from the Sandoz unit of Novartis (NYSE: NVS - News). As the first biotech drug to win approval, the biosimilar drug could be approved under exceptional rules that will not apply to other biotech generics. But even at that, the FDA did not want to issue a definitive opinion, fearing that ruling, even though applicable only in a single case, would be establishing a pathway for approving other biosimilars in the future.
That where the situation sits. There is precious little outrage from the public at large because the patents have not yet expired, so the public is not yet being prevented from enjoying cheaper drug prices. But as the expirations approach, the ambient noise about the issue will increase.
If the biotech industry gets its way, trials for biosimilars will approach the intensity of a full-fledged approval. This will drive the cost up somewhat and create long delays, but biotech and its industry organization, BIO, have a fair amount of political power. They will do what they can to protect their blockbuster drugs.
The Biotech Blockbuster Model
Biotech drugs, it should be noted, are billion dollar sellers because of their high prices. While that sounds like a truism, it is a different model than used for most of the pharma blockbusters. For example, the world’s biggest selling drug, Lipitor, is taken by the masses and the cost per patient is relatively low.
This is not true for EPO and the biotech drugs that address cancer. Since biologics need to be injected, they will be taken only by people who are seriously ill. Biologics target these particular markets for other reasons as well, including concentrated delivery to a relatively small physician base, in markets like rheumatoid arthritis, Crohn's disease, cancer, etc.
There are never enough people suffering from these diseases to make a traditional blockbuster drug such as Lipitor. Traditional pharma blockbusters exist because a huge fringe of healthy people with minor ailments and complaints, or borderline reading on diagnostic tests take drugs aimed at a serious illness. That happens in acid reflux, asthma, hypertension, high cholesterol, arthritis and minor pain, etc. where the fringe is many times bigger than the core. And those are the markets addressed by traditional blockbusters.
So to get a blockbuster in biologics, the drug needs to be sold for a lot of money. That is why Genentech’s (NYSE: DNA - News) and ImClone's (NasdaqGS: IMCL - News) prices are so expensive. Maybe overseas companies will be happy with smaller-revenue drugs, but a rigorous approval process would seriously eat into their margins and could make the whole field unappetizing to all but a few companies.
India versus China
Both India and China are well set up to take on this challenge, though India leads in having larger companies, like Dr. Reddy’s (NYSE: RDY - News), in a position to take on the formidable challenge of U.S. FDA trials. India’s Ranbaxy and Dr. Reddy’s have extensive experience dealing with FDA and EMEA. China’s biotech industry, on the other hand, is highly dispersed with no large companies in the mix. Companies seem to be partnering up, particularly drug makers with distribution firms, but they remain a long way from having any real powerhouses. 3SBio, for example, made less than $12 million on its version of EPO last year.
India may also have a small advantage in terms of infrastructure. But infrastructure and cost confer only a small edge, one that, when all is said and done, doesn’t matter all that much. After all, to make a biologic drug, one does not need to have a huge facility to produce the drugs. A few bioreactor vessels are all that is required. And the lower cost structure of drug development in Asia is not as big an advantage as it might seem, because the cost of goods is a minuscule fraction of sales prices for biologics – as is true for most medications.
Although nobody wants to talk much about margins, the consensus is that margins in the pharma industry run higher than 90% and some say higher than 95%. There have been some arguments made that biologics are different, but the financial reports don’t seem to bear this out.
The Future
We think the FDA will be forced to allow biosimilars in the near future. However, they are likely to be under tremendous pressure from the industry and that will result in an approval program that is somewhere in between a new drug approval and a generic approval, but very much closer to the former than to the latter. That means safety studies, clinical trials, etc. And that means extra costs and time in an area where your advantage is small.
One of the new factors that China will have to overcome is a fear engendered by quality lapses in non-drug areas. The pet food scare may have damaged China more than seems apparent at first blush. What will happen when China introduces a new drug that invades an American biotech’s turf? The commercials could be ugly. The close-on-its-heels toothpaste scare only reinforces the problem.
The key advantage China has is that they have a huge home market, including access to Asia, a market that is limited by how much people can afford to pay. But even at relatively low prices (extremely low prices when compared to the U.S.), 3SBio is able to make the same 90% margins on its version of EPO. Given the size of the U.S. market, Chinese companies like 3SBio will find the money (from outside its own treasury? with a U.S. partner?) to produce the drug.
In short, Amgen, Biogen (NasdaqGS: BIIB - News), and other biotechs with aging patents are very fortunate that the FDA is dragging its feet on the regulatory pathway for biosimilar biotech drugs. The lack of a pathway is the only real impediment to cheaper versions of drugs that will soon be off patent. In the normal world, Amgen would be in a world of financial trouble, because all of its products are about to lose IP protection and generic competition would trash its sales. Once the FDA defines the pathway to approval, the race will be on and companies from Asia will be joining the field.
Thursday June 14, 6:35 pm ET
ChinaBio Today submits: Biosimilars are the closest thing that the biotech world has to generic drugs. However, because biotech drugs are grown in cultures, rather than constructed out of chemicals like traditional pharma drugs, it is impossible to have a generic version of a biotech drug that is an exact reproduction of the original. This makes biosimilars difficult.
But biotech drugs are the most expensive drugs in the world, which makes generic versions of these famous medications very attractive.
At the moment, this is a dilemma. We know it will be solved, someday. We just don’t know how.
Because Asian drug centers, especially China and India, are known as low-cost havens of drug development, they are natural locations for developing these biosimilar drugs. Indeed, 3SBio (NasdaqGM: SSRX - News), the Chinese drug company that recently listed on the Nasdaq exchange (see story), is in the business of producing a version of Amgen’s (NasdaqGS: AMGN - News) EPO for the domestic Chinese market.
Amgen never patented EPO in China – it probably figured “What’s the point?” since Chinese IP laws were so weak at the time. This left 3SBio free to go ahead and make its own version of the drug to a population that, while huge, did not have much free cash to spend on a fairly esoteric drug. After all, the point of EPO is to lessen the effects of anemia in patients undergoing chemotherapy and dialysis, but the drug did nothing to cure the underlying cancer or kidney failure.
The patent protection on EPO and other early biotech drugs is running out. In fact, the patent on another Amgen biotech drug, Enbrel, expires in 2009. If these drugs were conventional medications, like Lipitor from Pfizer (NYSE: PFE - News), financial analysts would be climbing over each other to produce charts showing the rate at which Amgen’s revenues would fall in the coming years. Amgen has its own set of problems with EPO -- a well-documented story -- but the company remains much better off with its current difficulties than it would be if it faced imminent generic competition.
The reason that Amgen is off the hook on the patent expiration issue is that the FDA does not know how to devise a fair set of standards for approving biosimilars. Actually making one is fairly simple, despite the mystery in which biotech companies wrap their creations. Biotech companies obviously have a huge amount of self-interest in these rules. They believe that a biosimilar drug should, for the safety of the public, undergo a set of trials just as rigorous as the original. After all, they argue, the biosimilar drug is not the same, it is only similar. Small differences can make a life-and-death alteration. Safety is the goal, and all that. In all of this high-minded talk, no mention is ever made of the tremendous sums of money involved.
Consumers, tired of paying the enormous cost of these biotech drugs, argue for something less rigorous. The FDA, not sure what to do, stalls for time. In fact, the FDA dithered for so long over the first application for a biosimilar, a U.S. court told them to get moving. That initial application was for a human growth factor drug, Omnitrope from the Sandoz unit of Novartis (NYSE: NVS - News). As the first biotech drug to win approval, the biosimilar drug could be approved under exceptional rules that will not apply to other biotech generics. But even at that, the FDA did not want to issue a definitive opinion, fearing that ruling, even though applicable only in a single case, would be establishing a pathway for approving other biosimilars in the future.
That where the situation sits. There is precious little outrage from the public at large because the patents have not yet expired, so the public is not yet being prevented from enjoying cheaper drug prices. But as the expirations approach, the ambient noise about the issue will increase.
If the biotech industry gets its way, trials for biosimilars will approach the intensity of a full-fledged approval. This will drive the cost up somewhat and create long delays, but biotech and its industry organization, BIO, have a fair amount of political power. They will do what they can to protect their blockbuster drugs.
The Biotech Blockbuster Model
Biotech drugs, it should be noted, are billion dollar sellers because of their high prices. While that sounds like a truism, it is a different model than used for most of the pharma blockbusters. For example, the world’s biggest selling drug, Lipitor, is taken by the masses and the cost per patient is relatively low.
This is not true for EPO and the biotech drugs that address cancer. Since biologics need to be injected, they will be taken only by people who are seriously ill. Biologics target these particular markets for other reasons as well, including concentrated delivery to a relatively small physician base, in markets like rheumatoid arthritis, Crohn's disease, cancer, etc.
There are never enough people suffering from these diseases to make a traditional blockbuster drug such as Lipitor. Traditional pharma blockbusters exist because a huge fringe of healthy people with minor ailments and complaints, or borderline reading on diagnostic tests take drugs aimed at a serious illness. That happens in acid reflux, asthma, hypertension, high cholesterol, arthritis and minor pain, etc. where the fringe is many times bigger than the core. And those are the markets addressed by traditional blockbusters.
So to get a blockbuster in biologics, the drug needs to be sold for a lot of money. That is why Genentech’s (NYSE: DNA - News) and ImClone's (NasdaqGS: IMCL - News) prices are so expensive. Maybe overseas companies will be happy with smaller-revenue drugs, but a rigorous approval process would seriously eat into their margins and could make the whole field unappetizing to all but a few companies.
India versus China
Both India and China are well set up to take on this challenge, though India leads in having larger companies, like Dr. Reddy’s (NYSE: RDY - News), in a position to take on the formidable challenge of U.S. FDA trials. India’s Ranbaxy and Dr. Reddy’s have extensive experience dealing with FDA and EMEA. China’s biotech industry, on the other hand, is highly dispersed with no large companies in the mix. Companies seem to be partnering up, particularly drug makers with distribution firms, but they remain a long way from having any real powerhouses. 3SBio, for example, made less than $12 million on its version of EPO last year.
India may also have a small advantage in terms of infrastructure. But infrastructure and cost confer only a small edge, one that, when all is said and done, doesn’t matter all that much. After all, to make a biologic drug, one does not need to have a huge facility to produce the drugs. A few bioreactor vessels are all that is required. And the lower cost structure of drug development in Asia is not as big an advantage as it might seem, because the cost of goods is a minuscule fraction of sales prices for biologics – as is true for most medications.
Although nobody wants to talk much about margins, the consensus is that margins in the pharma industry run higher than 90% and some say higher than 95%. There have been some arguments made that biologics are different, but the financial reports don’t seem to bear this out.
The Future
We think the FDA will be forced to allow biosimilars in the near future. However, they are likely to be under tremendous pressure from the industry and that will result in an approval program that is somewhere in between a new drug approval and a generic approval, but very much closer to the former than to the latter. That means safety studies, clinical trials, etc. And that means extra costs and time in an area where your advantage is small.
One of the new factors that China will have to overcome is a fear engendered by quality lapses in non-drug areas. The pet food scare may have damaged China more than seems apparent at first blush. What will happen when China introduces a new drug that invades an American biotech’s turf? The commercials could be ugly. The close-on-its-heels toothpaste scare only reinforces the problem.
The key advantage China has is that they have a huge home market, including access to Asia, a market that is limited by how much people can afford to pay. But even at relatively low prices (extremely low prices when compared to the U.S.), 3SBio is able to make the same 90% margins on its version of EPO. Given the size of the U.S. market, Chinese companies like 3SBio will find the money (from outside its own treasury? with a U.S. partner?) to produce the drug.
In short, Amgen, Biogen (NasdaqGS: BIIB - News), and other biotechs with aging patents are very fortunate that the FDA is dragging its feet on the regulatory pathway for biosimilar biotech drugs. The lack of a pathway is the only real impediment to cheaper versions of drugs that will soon be off patent. In the normal world, Amgen would be in a world of financial trouble, because all of its products are about to lose IP protection and generic competition would trash its sales. Once the FDA defines the pathway to approval, the race will be on and companies from Asia will be joining the field.
marktkap. 210 million$
cash um die 120 million$!!!!!
eine hochprofitabele chinesische biotech firma!!!!
cash um die 120 million$!!!!!
eine hochprofitabele chinesische biotech firma!!!!
bin heute eingestiegen bei SSRX
Trading Spotlight
3SBio Inc. Announces Second Quarter 2007 Results
Wednesday August 8, 4:11 pm ET
SHENYANG, China, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX - News), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter ended June 30, 2007.
Second Quarter 2007 Financial Highlights:
-- Total net revenues increased 49.2% over the second quarter 2006 to
RMB43.1 million (US$5.7 million).
-- Net revenue from our flagship recombinant human erythropoietin products,
or EPO products, marketed under our EPIAO brand, increased 31.7% over
the second quarter 2006 to RMB30.0 million (US$3.9 million).
-- Net revenue from our protein-based therapeutic recombinant human
thrombopoietin products, or TPO products, marketed under our TPIAO
brand, increased 263.4% over the second quarter 2006 to RMB9.6 million
(US$1.3 million).
-- Operating income increased 69.6% over the second quarter 2006 to
RMB13.8 million (US$1.8 million).
-- Net income increased 268.9% over the second quarter 2006 to RMB23.3
million (US$3.1 million).
-- Net income per ordinary share and net income per American Depositary
Share ("ADS") for the second quarter 2007 were RMB0.15 (US$0.02) and
RMB1.07 (US$0.14) respectively, compared to RMB0.06 and RMB0.44
respectively for the second quarter 2006. Each ADS represents seven of
ordinary shares.
Dr. Jing Lou, chief executive officer of 3SBio, commented, "We are pleased to report another quarter of strong performance, driven by continued execution of our business strategy and solid growth in our core product portfolio. Sales in our flagship EPO product, EPIAO, increased 31.7% over the second quarter of 2006. According to the latest IMS Health data and our internal data, our EPIAO products continued to be the market leader in the first quarter of 2007 both in terms of revenues and sales volume, with market shares of approximately 36% and 30%, respectively. In addition, 3SBio was awarded exclusive access for all the solution dosage forms of EPIAO in 19 hospitals in the Beijing military hospital system under management by the Health Administration of the People's Liberation Army, further enhancing our market position and brand recognition. Our newest proprietary TPO product, TPIAO, continued to grow rapidly, up 263.4% over the second quarter of 2006, now representing 22.3% of our total revenue for the second quarter 2007."
"We have also advanced on a number of strategic and operational fronts, including development of our sales and marketing staff, operational systems integration, expansion of our manufacturing facilities, and improved financial reporting and compliance. Together, our steady execution and ability to deliver strong financial results quarter after quarter underpin our belief in our vision and strategy. I am confident that our continued focus on growth, margins and profitability will lead to positive returns for our shareholders."
Second Quarter 2007 Unaudited Financial Results
Net Revenues. Our net revenues amounted to RMB43.1 million (US$5.7 million) in the second quarter 2007 compared to RMB28.9 million net revenues for the second quarter 2006, representing an increase of 49.2%, primarily attributable to the continued growth of our flagship EPO product, EPIAO, as well as rapid sales growth in our TPO product, TPIAO. Net revenues from EPIAO increased by 31.7% from RMB22.8 million in the second quarter 2006 to RMB30.0 million (US$3.9 million) in the second quarter 2007. Net revenues from TPIAO increased 263.4% over the second quarter 2006 to RMB9.6 million (US$1.3 million). Our TPIAO products remained our second largest revenue contributor, accounting for 22.3% of total net revenues for the second quarter 2007 as compared to 9.2% in the second quarter 2006. Sales from our in-licensed Iron Sucrose supplement, Tietai, also continued to grow steadily, accounting for 1.3% of our overall sales in the second quarter 2007.
Gross Profit. Gross profit increased 51.5% to RMB39.1 million (US$5.1 million) for the second quarter 2007 from RMB25.8 million in the second quarter 2006. Gross margin was 90.8% in the second quarter 2007, up from 89.4% in the second quarter 2006.
Income from Operations. Operating income for the second quarter 2007 was RMB13.8 million (US$1.8 million), representing a 69.6% increase, compared to RMB8.1 million in the second quarter 2006, primarily due to increased operating leverage from continued sales growth. Operating margin for the second quarter 2007 was 31.9%, up from the 28.1% in the second quarter 2006, attributable to continued operational improvements in our manufacturing and sales platforms through increased product offerings and scale of operations
Operating Expenses. Our total operating expenses increased by 43.2% from RMB17.7 million in the second quarter of 2006 to RMB25.3 (US$3.3 million) in the second quarter 2007. This increase was primarily due to increased selling and promotional expenses resulting from continued sales growth. However, selling expenses as a percentage of revenue improved from 49.0% in the second quarter 2006 to 46.8% in the second quarter 2007 as a result of improved economies of scale.
Other Income (Expense), net. Net other income increased by RMB12.0 million in the second quarter of 2007, as compared to net other expense of RMB0.8 million in the second quarter of 2006, primarily as a result of increased interest income.
Income before Income Tax Expense and Minority Interests. As a result of the foregoing, our income before income tax expense and minority interests increased by 240.0% from RMB7.3 million in the second quarter 2006 to RMB25.0 million (US$3.3 million) for the second quarter 2007.
Income Tax Expense. Our income tax expense increased by 58.9% from RMB1.0 million for the second quarter 2006 to RMB1.6 million (US$0.2 million) for the second quarter 2007 mainly contributable to increased taxable income in the second quarter 2007 as a result of our increased profitability. The effective tax rate was 6.4% for the second quarter 2007, lower than the 13.6% for the prior year period, mainly attributable to more non-taxable interest income earned from IPO proceeds.
Net Income. As a result of the foregoing, our net income increased by 268.9% from RMB6.3 million for second quarter 2006 to RMB23.3 million (US$3.1 million) for the second quarter 2007.
Six months ended June 30, 2007 Unaudited Financial Results
Net revenues. Our net revenues increased by RMB21.5 million, or 37.8%, from RMB56.9 million for the six months ended June 30, 2006 to RMB78.4 million (US$10.3 million) for the six months ended June 30, 2007. This increase was primarily attributable to net revenues of RMB17.2 million (US$2.3 million) from TPIAO in the second half of 2007, our new product launched in January 2006, which has now become our second largest revenue contributor, accounting for 21.9% of total revenues for the six months ended June 30, 2007. We also experienced significant growth in our flagship EPIAO. Net revenues from EPIAO increased by RMB10.1 million, or 22.3%, to RMB55.1 million (US$7.2 million) for the first six months of 2007. The increase was primarily attributable to increased sales of our EPIAO in the second quarter. The resumption in sales growth of our EPIAO also demonstrated the contribution from our specialized oncology sales force newly set up in the first quarter of 2007, bolstering our efforts to focus on the growing oncology market in China.
Net Income. Net income for the first half of 2007 increased RMB25.7 million to RMB39.5 million (US$5.2 million) compared with RMB13.8 million for the same period in 2006. Net income per ordinary share and net income per ADS for the first half of 2007 increased to RMB0.28 (US$0.04) and RMB1.96 (US$0.26) respectively from RMB0.14 and RMB0.97 respectively in the comparable period in 2006.
Statement Regarding Unaudited Financial Information
The unaudited financial information set forth above is preliminary and subject to adjustments. Adjustments to the financial statements may be identified when audit work is performed for the year-end audit, which could result in significant differences from this preliminary unaudited financial information.
Currency Convenience Translation
For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB7.6120 to US$1.00, the noon buying rate for US dollars in effect on June 29, 2007 for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York.
Business Highlights
Pre-filled Syringe EPO - Plans to launch pre-filled syringe EPIAO products within 2007 are progressing in line with management expectations. In addition, in July 2007, 3SBio Inc. was awarded exclusive access for all the solution dosage forms of EPIAO in 19 hospitals in Beijing military hospital system under management by the Health Administration of the People's Liberation Army, further boosting market penetration and brand name recognition.
TPIAO Performance - TPIAO remains a key growth driver for 3SBio, as it continues to grow rapidly, reaching RMB9.6 million (US$1.3 million) in sales, accounting for 22.3% of total sales revenues for the second quarter of 2007.
Sales and Marketing - 3SBio has made good progress with the training of its specialized oncology and nephrology sales teams, with 80% of the sales force having completed training by the end of the second quarter, and the remaining 20% expected to complete training by the end of the third quarter 2007. 3SBio has also extended its marketing strategy with a detailed plan to expand its hospital penetration, targeting a total of 121 additional hospitals in 14 provinces. Furthermore, the company has built a specialized business development team to work with its strategic partners to enhance the company's marketing initiatives in overseas markets.
New Plant and Upgrade of Current Facilities - Construction of 3SBio's new manufacturing facility in Shenyang is on schedule, with ground breaking and the first phase of the development plan on track to be completed by the end of 2007. The hiring of European consultants to assist with EMEA compliance is currently under way, and the foundation of the new facility is expected to be completed by the end of 2007. Upgrades to our other facilities to meet EMEA requirements are also on target, and will be near completion in 2008.
Conference Call
3SBio senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on Thursday, August 9, 2007 to discuss its 2007 second quarter financial results and recent business activity. The conference call may be accessed by calling (US) +1 480 629 9564 / (UK) +44 (0)20 8515 2301 / (HK) +852 3009 5027. A telephone replay will be available shortly after the call until August 23, 2007 at (US) +1 303 590 3030/ (UK) +44 (0)20 7154 2833, Passcode: 3765910; and (HK) +852 2287 4304, Passcode: 107 110#.
A live webcast of the conference call and replay will be available on the investor relations page of 3SBio's website at www.3sbio.com/en/News/ShowInfo_nnn5.aspx?ID=64 .
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at www.3sbio.com
Safe Harbor Statement
Statements in this release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon 3SBio management's current expectations, and actual results could differ materially. Among the factors that could cause 3SBio's actual results to differ from what the company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors that may affect the 3SBio's financial results, please refer to the company's filings with the Securities and Exchange Commission at www.sec.gov. 3SBio undertakes no obligation to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Investor Contact:
Clara Mak, CFO
3SBio Inc.
No.3 A1, Road 10,
Shenyang Development Zone
Shenyang, China 110027
+86 (24) 2581 1820
IR@3sbio.com
www.3SBio.com
Investor Relations (US):
Mahmoud Siddig, Director
Taylor Rafferty
205 Lexington Avenue
8th Floor
New York, NY 10016
+1 (212) 889-4350
3sbio@taylor-rafferty.com
www.taylor-rafferty.com
Investor Relations (HK):
Ruby Yim, Managing Director
Taylor Rafferty
3213 Cosco Tower
183 Queen's Road Central
Hong Kong, China
+852 3196 3712
3sbio@taylor-rafferty.com
www.taylor-rafferty.com
Media Contact:
John Dooley
Taylor Rafferty
205 Lexington Avenue
8th Floor
New York, NY 10016
+1 (212) 889-4350
3sbio@taylor-rafferty.com
www.taylor-rafferty.com
3SBio Inc. and subsidiaries
Consolidated balance sheets
(expressed in thousands)
December 31 June 30 June 30
2006 2007 2007
Audited Unaudited Unaudited
RMB RMB US$
Assets
Current assets
Cash and cash equivalents 25,372 870,375 114,342
Accounts receivable, less
allowance for doubtful accounts:
December 31, 2006 - RMB4,871;
June 30, 2007 - RMB4,946
(US$650) 37,402 48,510 6,373
Inventories 8,682 6,929 910
Prepaid expenses and other
receivables 14,872 8,021 1,054
Deferred tax assets 2,154 1,660 218
Total current assets 88,482 935,495 122,897
Long term investment - 10,012 1,315
Property, plant and equipment, net 43,142 42,876 5,633
Lease prepayments 9,600 9,423 1,238
Deferred tax assets 1,251 938 123
Total assets 142,475 998,744 131,206
Liabilities
Current liabilities
Short-term bank loans 15,000 25,000 3,284
Accounts payable 1,769 1,935 254
Deferred grant income 611 374 49
Accrued expenses and other payables 16,318 30,700 4,033
Income tax payable 1,167 2,884 379
Amounts due to related parties 4,225 1,023 134
Other current liabilities 92 56 7
Total current liabilities 39,182 61,972 8,140
Long-term bank loans 25,000 - -
Deferred grant income 3,900 3,712 488
Other liabilities 585 557 73
Total liabilities 68,667 66,241 8,701
Commitments and contingencies
Minority interests 474 559 73
Shareholders' equity
Share capital - ordinary shares
US$0.0001 par value, 500,000,000
shares authorized, 152,084,155
shares issued and outstanding
as of June 30, 2007 80 122 16
Additional paid-in capital 80,286 915,264 120,240
Accumulated other
comprehensive loss - (15,903) (2,089)
(Accumulated deficit)/
Retained earnings (7,032) 32,461 4,265
Total shareholders' equity 73,334 931,944 122,432
Total liabilities and
shareholders' equity 142,475 998,744 131,206
3SBio Inc. and subsidiaries
Unaudited quarterly consolidated statements of income
(expressed in thousands, except per share , per ADS and other share and
ADS data)
For the Three Months Ended June 30,
2006 2007 2007
RMB RMB US$
Net Revenues:
EPIAO 22,791 30,008 3,942
TPIAO 2,647 9,618 1,264
Intefen 817 811 107
Inleusin 300 272 36
Export 2,199 1,645 216
Iron 33 581 76
Others 66 118 15
Total 28,853 43,053 5,656
Cost of revenues (3,061) (3,972) (522)
Gross profit 25,792 39,081 5,134
Operating expenses
Research and development
expense (1,156) (1,876) (246)
Sales, marketing and
distribution expense (14,142) (20,141) (2,646)
General and administrative expense (2,388) (3,314) (435)
Total operating expenses (17,686) (25,331) (3,327)
Operating income 8,106 13,750 1,807
Other (expense)/income, net
Interest income 69 11,242 1,477
Interest expense (1,178) (263) (35)
Grant income 535 269 35
Others (189) (31) (4)
Total other (expense)/income, net (763) 11,217 1,473
Income before income tax expense
and minority interests 7,343 24,967 3,280
Income tax expense (1,001) (1,591) (209)
Income before minority interests 6,342 23,376 3,071
Minority interests, net of tax (15) (35) (5)
Net income 6,327 23,341 3,066
Net income per share:
Basic and diluted 0.06 0.15 0.02
Basic weighted average number
of shares outstanding 100,000,998 152,084,155 152,084,155
Effect of dilutive
potential shares - 13,071 13,071
Diluted weighted average
number of shares outstanding 100,000,998 152,097,226 152,097,226
Net income per ADS:
Basic and diluted 0.44 1.07 0.14
Basic weighted average number
of ADSs outstanding 14,285,857 21,726,308 21,726,308
Effect of dilutive
potential ADSs - 1,827 1,827
Diluted weighted average
number of ADSs outstanding 14,285,857 21,728,135 21,728,135
3SBio Inc. and subsidiaries
Unaudited consolidated statements of income
(expressed in thousands, except per share per ADS and other share and ADS
data)
For the Six Months Ended June 30,
2006 2007 2007
RMB RMB US$
Net Revenues:
EPIAO 45,075 55,126 7,242
TPIAO 4,958 17,184 2,258
Intefen 2,404 1,766 232
Inleusin 623 572 75
Export 3,593 2,295 301
Iron - 1,126 148
Others 276 357 47
Total 56,929 78,426 10,303
Cost of revenues (5,719) (6,902) (907)
Gross profit 51,210 71,524 9,396
Operating expenses
Research and development expense (1,588) (4,063) (534)
Sales, marketing and
distribution expense (26,731) (35,714) (4,692)
General and administrative expense (5,645) (6,405) (841)
Total operating expenses (33,964) (46,182) (6,067)
Operating income 17,246 25,342 3,329
Other (expense)/ income, net
Interest income 134 17,458 2,293
Interest expense (2,512) (672) (88)
Grant income 1,269 781 103
Others (180) 18 2
Total other (expense)/income, net (1,289) 17,585 2,310
Income before income tax expense
and minority interests 15,957 42,927 5,639
Income tax expense (2,177) (3,349) (440)
Income before minority interests 13,780 39,578 5,199
Minority interests, net of tax 16 (85) (11)
Net income 13,796 39,493 5,188
Net income per share:
Basic and diluted 0.14 0.28 0.04
Basic weighted average number
of shares outstanding 100,000,998 141,105,129 141,105,129
Effect of dilutive
potential shares - 13,143 13,143
Diluted weighted average
number of shares outstanding 100,000,998 141,118,272 141,118,272
Net income per ADS:
Basic and diluted 0.97 1.96 0.26
Basic weighted average number
of ADSs outstanding 14,285,857 20,157,876 20,157,876
Effect of dilutive
potential ADSs - 1,877 1,877
Diluted weighted average number
of ADSs outstanding 14,285,857 20,159,753 20,159,753
--------------------------------------------------------------------------------
Source: 3SBio Inc.
Wednesday August 8, 4:11 pm ET
SHENYANG, China, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX - News), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter ended June 30, 2007.
Second Quarter 2007 Financial Highlights:
-- Total net revenues increased 49.2% over the second quarter 2006 to
RMB43.1 million (US$5.7 million).
-- Net revenue from our flagship recombinant human erythropoietin products,
or EPO products, marketed under our EPIAO brand, increased 31.7% over
the second quarter 2006 to RMB30.0 million (US$3.9 million).
-- Net revenue from our protein-based therapeutic recombinant human
thrombopoietin products, or TPO products, marketed under our TPIAO
brand, increased 263.4% over the second quarter 2006 to RMB9.6 million
(US$1.3 million).
-- Operating income increased 69.6% over the second quarter 2006 to
RMB13.8 million (US$1.8 million).
-- Net income increased 268.9% over the second quarter 2006 to RMB23.3
million (US$3.1 million).
-- Net income per ordinary share and net income per American Depositary
Share ("ADS") for the second quarter 2007 were RMB0.15 (US$0.02) and
RMB1.07 (US$0.14) respectively, compared to RMB0.06 and RMB0.44
respectively for the second quarter 2006. Each ADS represents seven of
ordinary shares.
Dr. Jing Lou, chief executive officer of 3SBio, commented, "We are pleased to report another quarter of strong performance, driven by continued execution of our business strategy and solid growth in our core product portfolio. Sales in our flagship EPO product, EPIAO, increased 31.7% over the second quarter of 2006. According to the latest IMS Health data and our internal data, our EPIAO products continued to be the market leader in the first quarter of 2007 both in terms of revenues and sales volume, with market shares of approximately 36% and 30%, respectively. In addition, 3SBio was awarded exclusive access for all the solution dosage forms of EPIAO in 19 hospitals in the Beijing military hospital system under management by the Health Administration of the People's Liberation Army, further enhancing our market position and brand recognition. Our newest proprietary TPO product, TPIAO, continued to grow rapidly, up 263.4% over the second quarter of 2006, now representing 22.3% of our total revenue for the second quarter 2007."
"We have also advanced on a number of strategic and operational fronts, including development of our sales and marketing staff, operational systems integration, expansion of our manufacturing facilities, and improved financial reporting and compliance. Together, our steady execution and ability to deliver strong financial results quarter after quarter underpin our belief in our vision and strategy. I am confident that our continued focus on growth, margins and profitability will lead to positive returns for our shareholders."
Second Quarter 2007 Unaudited Financial Results
Net Revenues. Our net revenues amounted to RMB43.1 million (US$5.7 million) in the second quarter 2007 compared to RMB28.9 million net revenues for the second quarter 2006, representing an increase of 49.2%, primarily attributable to the continued growth of our flagship EPO product, EPIAO, as well as rapid sales growth in our TPO product, TPIAO. Net revenues from EPIAO increased by 31.7% from RMB22.8 million in the second quarter 2006 to RMB30.0 million (US$3.9 million) in the second quarter 2007. Net revenues from TPIAO increased 263.4% over the second quarter 2006 to RMB9.6 million (US$1.3 million). Our TPIAO products remained our second largest revenue contributor, accounting for 22.3% of total net revenues for the second quarter 2007 as compared to 9.2% in the second quarter 2006. Sales from our in-licensed Iron Sucrose supplement, Tietai, also continued to grow steadily, accounting for 1.3% of our overall sales in the second quarter 2007.
Gross Profit. Gross profit increased 51.5% to RMB39.1 million (US$5.1 million) for the second quarter 2007 from RMB25.8 million in the second quarter 2006. Gross margin was 90.8% in the second quarter 2007, up from 89.4% in the second quarter 2006.
Income from Operations. Operating income for the second quarter 2007 was RMB13.8 million (US$1.8 million), representing a 69.6% increase, compared to RMB8.1 million in the second quarter 2006, primarily due to increased operating leverage from continued sales growth. Operating margin for the second quarter 2007 was 31.9%, up from the 28.1% in the second quarter 2006, attributable to continued operational improvements in our manufacturing and sales platforms through increased product offerings and scale of operations
Operating Expenses. Our total operating expenses increased by 43.2% from RMB17.7 million in the second quarter of 2006 to RMB25.3 (US$3.3 million) in the second quarter 2007. This increase was primarily due to increased selling and promotional expenses resulting from continued sales growth. However, selling expenses as a percentage of revenue improved from 49.0% in the second quarter 2006 to 46.8% in the second quarter 2007 as a result of improved economies of scale.
Other Income (Expense), net. Net other income increased by RMB12.0 million in the second quarter of 2007, as compared to net other expense of RMB0.8 million in the second quarter of 2006, primarily as a result of increased interest income.
Income before Income Tax Expense and Minority Interests. As a result of the foregoing, our income before income tax expense and minority interests increased by 240.0% from RMB7.3 million in the second quarter 2006 to RMB25.0 million (US$3.3 million) for the second quarter 2007.
Income Tax Expense. Our income tax expense increased by 58.9% from RMB1.0 million for the second quarter 2006 to RMB1.6 million (US$0.2 million) for the second quarter 2007 mainly contributable to increased taxable income in the second quarter 2007 as a result of our increased profitability. The effective tax rate was 6.4% for the second quarter 2007, lower than the 13.6% for the prior year period, mainly attributable to more non-taxable interest income earned from IPO proceeds.
Net Income. As a result of the foregoing, our net income increased by 268.9% from RMB6.3 million for second quarter 2006 to RMB23.3 million (US$3.1 million) for the second quarter 2007.
Six months ended June 30, 2007 Unaudited Financial Results
Net revenues. Our net revenues increased by RMB21.5 million, or 37.8%, from RMB56.9 million for the six months ended June 30, 2006 to RMB78.4 million (US$10.3 million) for the six months ended June 30, 2007. This increase was primarily attributable to net revenues of RMB17.2 million (US$2.3 million) from TPIAO in the second half of 2007, our new product launched in January 2006, which has now become our second largest revenue contributor, accounting for 21.9% of total revenues for the six months ended June 30, 2007. We also experienced significant growth in our flagship EPIAO. Net revenues from EPIAO increased by RMB10.1 million, or 22.3%, to RMB55.1 million (US$7.2 million) for the first six months of 2007. The increase was primarily attributable to increased sales of our EPIAO in the second quarter. The resumption in sales growth of our EPIAO also demonstrated the contribution from our specialized oncology sales force newly set up in the first quarter of 2007, bolstering our efforts to focus on the growing oncology market in China.
Net Income. Net income for the first half of 2007 increased RMB25.7 million to RMB39.5 million (US$5.2 million) compared with RMB13.8 million for the same period in 2006. Net income per ordinary share and net income per ADS for the first half of 2007 increased to RMB0.28 (US$0.04) and RMB1.96 (US$0.26) respectively from RMB0.14 and RMB0.97 respectively in the comparable period in 2006.
Statement Regarding Unaudited Financial Information
The unaudited financial information set forth above is preliminary and subject to adjustments. Adjustments to the financial statements may be identified when audit work is performed for the year-end audit, which could result in significant differences from this preliminary unaudited financial information.
Currency Convenience Translation
For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB7.6120 to US$1.00, the noon buying rate for US dollars in effect on June 29, 2007 for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York.
Business Highlights
Pre-filled Syringe EPO - Plans to launch pre-filled syringe EPIAO products within 2007 are progressing in line with management expectations. In addition, in July 2007, 3SBio Inc. was awarded exclusive access for all the solution dosage forms of EPIAO in 19 hospitals in Beijing military hospital system under management by the Health Administration of the People's Liberation Army, further boosting market penetration and brand name recognition.
TPIAO Performance - TPIAO remains a key growth driver for 3SBio, as it continues to grow rapidly, reaching RMB9.6 million (US$1.3 million) in sales, accounting for 22.3% of total sales revenues for the second quarter of 2007.
Sales and Marketing - 3SBio has made good progress with the training of its specialized oncology and nephrology sales teams, with 80% of the sales force having completed training by the end of the second quarter, and the remaining 20% expected to complete training by the end of the third quarter 2007. 3SBio has also extended its marketing strategy with a detailed plan to expand its hospital penetration, targeting a total of 121 additional hospitals in 14 provinces. Furthermore, the company has built a specialized business development team to work with its strategic partners to enhance the company's marketing initiatives in overseas markets.
New Plant and Upgrade of Current Facilities - Construction of 3SBio's new manufacturing facility in Shenyang is on schedule, with ground breaking and the first phase of the development plan on track to be completed by the end of 2007. The hiring of European consultants to assist with EMEA compliance is currently under way, and the foundation of the new facility is expected to be completed by the end of 2007. Upgrades to our other facilities to meet EMEA requirements are also on target, and will be near completion in 2008.
Conference Call
3SBio senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on Thursday, August 9, 2007 to discuss its 2007 second quarter financial results and recent business activity. The conference call may be accessed by calling (US) +1 480 629 9564 / (UK) +44 (0)20 8515 2301 / (HK) +852 3009 5027. A telephone replay will be available shortly after the call until August 23, 2007 at (US) +1 303 590 3030/ (UK) +44 (0)20 7154 2833, Passcode: 3765910; and (HK) +852 2287 4304, Passcode: 107 110#.
A live webcast of the conference call and replay will be available on the investor relations page of 3SBio's website at www.3sbio.com/en/News/ShowInfo_nnn5.aspx?ID=64 .
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at www.3sbio.com
Safe Harbor Statement
Statements in this release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon 3SBio management's current expectations, and actual results could differ materially. Among the factors that could cause 3SBio's actual results to differ from what the company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors that may affect the 3SBio's financial results, please refer to the company's filings with the Securities and Exchange Commission at www.sec.gov. 3SBio undertakes no obligation to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Investor Contact:
Clara Mak, CFO
3SBio Inc.
No.3 A1, Road 10,
Shenyang Development Zone
Shenyang, China 110027
+86 (24) 2581 1820
IR@3sbio.com
www.3SBio.com
Investor Relations (US):
Mahmoud Siddig, Director
Taylor Rafferty
205 Lexington Avenue
8th Floor
New York, NY 10016
+1 (212) 889-4350
3sbio@taylor-rafferty.com
www.taylor-rafferty.com
Investor Relations (HK):
Ruby Yim, Managing Director
Taylor Rafferty
3213 Cosco Tower
183 Queen's Road Central
Hong Kong, China
+852 3196 3712
3sbio@taylor-rafferty.com
www.taylor-rafferty.com
Media Contact:
John Dooley
Taylor Rafferty
205 Lexington Avenue
8th Floor
New York, NY 10016
+1 (212) 889-4350
3sbio@taylor-rafferty.com
www.taylor-rafferty.com
3SBio Inc. and subsidiaries
Consolidated balance sheets
(expressed in thousands)
December 31 June 30 June 30
2006 2007 2007
Audited Unaudited Unaudited
RMB RMB US$
Assets
Current assets
Cash and cash equivalents 25,372 870,375 114,342
Accounts receivable, less
allowance for doubtful accounts:
December 31, 2006 - RMB4,871;
June 30, 2007 - RMB4,946
(US$650) 37,402 48,510 6,373
Inventories 8,682 6,929 910
Prepaid expenses and other
receivables 14,872 8,021 1,054
Deferred tax assets 2,154 1,660 218
Total current assets 88,482 935,495 122,897
Long term investment - 10,012 1,315
Property, plant and equipment, net 43,142 42,876 5,633
Lease prepayments 9,600 9,423 1,238
Deferred tax assets 1,251 938 123
Total assets 142,475 998,744 131,206
Liabilities
Current liabilities
Short-term bank loans 15,000 25,000 3,284
Accounts payable 1,769 1,935 254
Deferred grant income 611 374 49
Accrued expenses and other payables 16,318 30,700 4,033
Income tax payable 1,167 2,884 379
Amounts due to related parties 4,225 1,023 134
Other current liabilities 92 56 7
Total current liabilities 39,182 61,972 8,140
Long-term bank loans 25,000 - -
Deferred grant income 3,900 3,712 488
Other liabilities 585 557 73
Total liabilities 68,667 66,241 8,701
Commitments and contingencies
Minority interests 474 559 73
Shareholders' equity
Share capital - ordinary shares
US$0.0001 par value, 500,000,000
shares authorized, 152,084,155
shares issued and outstanding
as of June 30, 2007 80 122 16
Additional paid-in capital 80,286 915,264 120,240
Accumulated other
comprehensive loss - (15,903) (2,089)
(Accumulated deficit)/
Retained earnings (7,032) 32,461 4,265
Total shareholders' equity 73,334 931,944 122,432
Total liabilities and
shareholders' equity 142,475 998,744 131,206
3SBio Inc. and subsidiaries
Unaudited quarterly consolidated statements of income
(expressed in thousands, except per share , per ADS and other share and
ADS data)
For the Three Months Ended June 30,
2006 2007 2007
RMB RMB US$
Net Revenues:
EPIAO 22,791 30,008 3,942
TPIAO 2,647 9,618 1,264
Intefen 817 811 107
Inleusin 300 272 36
Export 2,199 1,645 216
Iron 33 581 76
Others 66 118 15
Total 28,853 43,053 5,656
Cost of revenues (3,061) (3,972) (522)
Gross profit 25,792 39,081 5,134
Operating expenses
Research and development
expense (1,156) (1,876) (246)
Sales, marketing and
distribution expense (14,142) (20,141) (2,646)
General and administrative expense (2,388) (3,314) (435)
Total operating expenses (17,686) (25,331) (3,327)
Operating income 8,106 13,750 1,807
Other (expense)/income, net
Interest income 69 11,242 1,477
Interest expense (1,178) (263) (35)
Grant income 535 269 35
Others (189) (31) (4)
Total other (expense)/income, net (763) 11,217 1,473
Income before income tax expense
and minority interests 7,343 24,967 3,280
Income tax expense (1,001) (1,591) (209)
Income before minority interests 6,342 23,376 3,071
Minority interests, net of tax (15) (35) (5)
Net income 6,327 23,341 3,066
Net income per share:
Basic and diluted 0.06 0.15 0.02
Basic weighted average number
of shares outstanding 100,000,998 152,084,155 152,084,155
Effect of dilutive
potential shares - 13,071 13,071
Diluted weighted average
number of shares outstanding 100,000,998 152,097,226 152,097,226
Net income per ADS:
Basic and diluted 0.44 1.07 0.14
Basic weighted average number
of ADSs outstanding 14,285,857 21,726,308 21,726,308
Effect of dilutive
potential ADSs - 1,827 1,827
Diluted weighted average
number of ADSs outstanding 14,285,857 21,728,135 21,728,135
3SBio Inc. and subsidiaries
Unaudited consolidated statements of income
(expressed in thousands, except per share per ADS and other share and ADS
data)
For the Six Months Ended June 30,
2006 2007 2007
RMB RMB US$
Net Revenues:
EPIAO 45,075 55,126 7,242
TPIAO 4,958 17,184 2,258
Intefen 2,404 1,766 232
Inleusin 623 572 75
Export 3,593 2,295 301
Iron - 1,126 148
Others 276 357 47
Total 56,929 78,426 10,303
Cost of revenues (5,719) (6,902) (907)
Gross profit 51,210 71,524 9,396
Operating expenses
Research and development expense (1,588) (4,063) (534)
Sales, marketing and
distribution expense (26,731) (35,714) (4,692)
General and administrative expense (5,645) (6,405) (841)
Total operating expenses (33,964) (46,182) (6,067)
Operating income 17,246 25,342 3,329
Other (expense)/ income, net
Interest income 134 17,458 2,293
Interest expense (2,512) (672) (88)
Grant income 1,269 781 103
Others (180) 18 2
Total other (expense)/income, net (1,289) 17,585 2,310
Income before income tax expense
and minority interests 15,957 42,927 5,639
Income tax expense (2,177) (3,349) (440)
Income before minority interests 13,780 39,578 5,199
Minority interests, net of tax 16 (85) (11)
Net income 13,796 39,493 5,188
Net income per share:
Basic and diluted 0.14 0.28 0.04
Basic weighted average number
of shares outstanding 100,000,998 141,105,129 141,105,129
Effect of dilutive
potential shares - 13,143 13,143
Diluted weighted average
number of shares outstanding 100,000,998 141,118,272 141,118,272
Net income per ADS:
Basic and diluted 0.97 1.96 0.26
Basic weighted average number
of ADSs outstanding 14,285,857 20,157,876 20,157,876
Effect of dilutive
potential ADSs - 1,877 1,877
Diluted weighted average number
of ADSs outstanding 14,285,857 20,159,753 20,159,753
--------------------------------------------------------------------------------
Source: 3SBio Inc.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 228 | ||
| 114 | ||
| 101 | ||
| 80 | ||
| 79 | ||
| 60 | ||
| 49 | ||
| 47 | ||
| 42 | ||
| 35 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 32 | ||
| 29 | ||
| 26 | ||
| 25 | ||
| 24 | ||
| 23 | ||
| 20 | ||
| 18 | ||
| 17 |
